Disclosed herein are oestratrienes of general formula (I), wherein the variables are defined in the specification, and the use thereof in in the treatment of oestrogen-dependent disorders. Exemplary compounds include: 11?-fluoro-17?-methyl-7?-[5-[(2R)-2-(6,6,7,7,7-pentafluoroheptyl)-1-pyrrolidinyl]pentyl]oestra-1,3,5(10)-triene-3,17?-diol; and 11?-fluoro-17?-methyl-7?-[5-[methyl(8,8,9,9,9-pentafluorononyl)amino]pentyl]oestra- 1,3,5(10)-triene-3,17?-diol.